Radboud University Medical Center, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands; Dutch Institute for Clinical Auditing (DICA), Scientific Bureau, Leiden, the Netherlands.
Center of Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Department of Gynecology, Amsterdam, the Netherlands.
Eur J Surg Oncol. 2021 Jul;47(7):1691-1697. doi: 10.1016/j.ejso.2021.01.019. Epub 2021 Feb 5.
The Dutch Gynecological Oncology Audit (DGOA) was initiated in 2014 to serve as a nationwide audit, which registers the four most prevalent gynecological malignancies. This study presents the first results of clinical auditing for ovarian cancer in the Netherlands.
The Dutch Gynecological Oncology Audit is facilitated by the Dutch Institute of Clinical Auditing (DICA) and run by a scientific committee. Items are collected through a web-based registration based on a set of predefined quality indicators. Results of quality indicators are shown, and benchmarked information is given back to the user. Data verification was done in 2016.
Between January 01, 2014 and December 31, 2018, 6535 patients with ovarian cancer were registered. The case ascertainment was 98.3% in 2016. The number of patients with ovarian cancer who start therapy within 28 days decreased over time from 68.7% in 2014 to 62.7% in 2018 (p < 0.001). The percentage of patients with primary cytoreductive surgery decreased over time (57.8%-39.7%, P < 0.001). However, patients with complete primary cytoreductive surgery improved over time (53.5%-69.1%, P < 0.001). Other quality indicators did not significantly change over time.
The Dutch Gynecological Oncology Audit provides valuable data on the quality of care on patients with ovarian cancer in the Netherlands. Data show variation between hospitals with regard to pre-determined quality indicators. Results of 'best practices' will be shared with all participants of the clinical audit with the aim of improving quality of care nationwide.
荷兰妇科肿瘤学审计（DGOA）于 2014 年启动，旨在作为一项全国性审计，登记四种最常见的妇科恶性肿瘤。本研究报告了荷兰卵巢癌临床审计的初步结果。
荷兰妇科肿瘤学审计由荷兰临床审计研究所（DICA）协助，并由一个科学委员会管理。通过基于一组预设质量指标的网络注册收集项目。展示质量指标的结果，并向用户提供基准信息。数据验证于 2016 年进行。
2014 年 1 月 1 日至 2018 年 12 月 31 日，登记了 6535 例卵巢癌患者。2016 年病例确定率为 98.3%。在 28 天内开始治疗的卵巢癌患者数量随着时间的推移从 2014 年的 68.7%下降到 2018 年的 62.7%（p<0.001）。行初次肿瘤细胞减灭术的患者比例随着时间的推移而下降（57.8%-39.7%，P<0.001）。然而，行完全初次肿瘤细胞减灭术的患者比例随着时间的推移而增加（53.5%-69.1%，P<0.001）。其他质量指标在时间上没有显著变化。
荷兰妇科肿瘤学审计为荷兰卵巢癌患者的护理质量提供了有价值的数据。数据显示，在预定的质量指标方面，医院之间存在差异。“最佳实践”的结果将与临床审计的所有参与者共享，目的是在全国范围内提高护理质量。
